An integrated early care pathway for autism
- PMID: 35303486
- DOI: 10.1016/S2352-4642(22)00037-2
An integrated early care pathway for autism
Abstract
In this Viewpoint, we argue for the need to reconceptualise an integrated early-care provision for autistic children in the light of their enduring support needs and relevant new findings from developmental and intervention research. This model goes beyond short-term reactive care to outline an early proactive, evidenced, developmentally phased, and scalable programme of support for autistic children and their families from the earliest opportunity, with timely access to later step-up care when needed. We also integrate this model with emerging opportunities from data science and digital health technologies as a potential facilitator of such a pathway. Building on this work, we argue that the best current autism intervention evidence can be integrated with concepts and evidence gained in the management of other enduring health conditions to support an autistic child and their family through their early development. The aim is to improve those children's social communication abilities, expand their range and flexibility of interests, and mitigate any negative impacts of sensory difficulties and restricted, repetitive behaviours on the child and their family wellbeing. The pathway solutions described could also be adapted for older adolescents and adults and could be used within the health systems of different countries, including within low-income and middle-income contexts.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests JG is a director of IMPACT CiC, a not-for-profit community interest company set up to provide professional training in the paediatric autism communication therapy intervention for the NHS and internationally. JA and SB are Directors and shareholders of CareLoop Health Ltd, which develops and markets digital therapeutics for schizophrenia and a digital screening app for postnatal depression. JA and SB are also directors of Affigo CIC, a community interest company that develops and markets digital remote monitoring for schizophrenia and a digital screening app for postnatal depression (Affigo CIC was the predecessor to CareLoop Health Ltd and will cease to exist from May 1, 2022). The Affigo and Careloop companies disclosed have no relevance to autism or the topic under discussion here. JG is a UK National Institute for Health Research (NIHR) Senior Investigator and SB is an NIHR Research Professor. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
